Applications of 3-[N,N-Bis(2-Hydroxyethyl)Amino]-2-Hydroxy-1-Propanesulfonic Acid in Industrial Manufacturing

As a direct manufacturer specializing in the production of high-purity 3-[N,N-Bis(2-Hydroxyethyl)Amino]-2-Hydroxy-1-Propanesulfonic Acid (commonly known as DiHEPPS or DIHEPS), we supply this sulfonic acid buffer to several global industries where stringent consistency and defined chemical behaviors are critical in downstream processing. Below, we detail its integrated roles in four key sectors, covering compliance, recommended formulation, processing stages, and resulting finished products.

1. In Vitro Diagnostic (IVD) Buffer Manufacturing

IVD reagent manufacturers rely on DiHEPPS for highly stable and pH-precise buffer preparations, where minimal ionic strength fluctuation and compatibility with sensitive enzymes and antibodies are prerequisites. Producers incorporate this buffer during the aqueous phase of diluent and stabilization solutions to ensure uniform assay performance and reduce lot-to-lot variation in equipment like clinical analyzers.

Industry compliance standards

• ISO 13485:2016 Medical device quality management
• EN 13612 Performance evaluation of IVD medical devices
• CLSI GP29-A IVD reagent quality guidelines
• 21 CFR Part 820 FDA QSR for medical device manufacturing

Typical usage ratio

• Commonly 5–50 mM in working buffer; concentrations adjusted according to target pH range and instrument assay volume requirements

Downstream process integration

• Buffer salt addition during initial tank batching, adjusted after component pre-dissolution and before sterile filtration; introduced before sterile packaging or lyophilization steps

Final product types

• Clinical chemistry reagent kits
• PCR/qPCR assay buffers
• ELISA and immunoassay reagent packs
• Automated analyzer system diluents

2. Biopharmaceutical Protein Purification & Formulation

Downstream process engineers within biopharma facilities utilize DIHEPS buffers for preparative chromatography and protein formulation, benefiting from its low metal ion binding and minimal UV interference. The buffer's chemical profile supports reproducibility during capture, intermediate and polishing chromatography steps, and often in protein storage formulations that demand non-reactive, stable environments.

Industry compliance standards

• ICH Q7 GMP for active pharmaceutical ingredients
• USP <1043> Ancillary materials for cell culture and bioprocessing
• EMA Guideline on Manufacture of Biological Medicinal Products for Human Use
• ISO 9001:2015 Quality management systems

Typical usage ratio

• Usually 10–50 mM buffer concentration in mobile phase solutions for purification steps; higher concentrations (up to 100 mM) for formulation/stability purposes based on protein charge and pI

Downstream process integration

• Introduced in upstream stock solution prep, then filtered and applied as equilibration, wash, or elution buffer in column chromatography or as a component of final fill formulation prior to lyophilization or sterile vialing

Final product types

• Monoclonal antibody purified bulk
• Recombinant protein injectable formulations
• Vaccine component buffer solutions
• Ready-to-use protein storage buffer vials

3. Cell Culture Media & Vaccine Production

Cultured cell and vaccine product manufacturers deploy this sulfonic acid buffer to tightly regulate media pH throughout fermentation or production runs. With exceptionally low cytotoxicity and minimal side-reactivity, DiHEPPS is compatible with serum-free and chemically defined media for both microbial and mammalian cell-based systems under regulated bioprocessing conditions.

Industry compliance standards

• USP <1043> Ancillary materials in manufacturing
• ISO 14644 Cleanroom and controlled environments
• 21 CFR Parts 210/211 cGMP for finished pharmaceuticals
• WHO Technical Report Series (TRS) Guidelines on vaccine manufacturing

Typical usage ratio

• 5–40 mM as the primary buffer in complex media; fine-tuned by cell line pH tolerance and culture system scale

Downstream process integration

• Added during base media formulation stage, prior to sterilization and aseptic filter transfer; monitored in-line by pH sensing during fermentation/bioreactor runs

Final product types

• Mammalian cell culture basal and feeding media
• Virus attenuation and vaccine growth media
• Cellular therapy ingredient solutions
• Pilot/bulk vaccine bioprocess feed additives

4. Electrophoresis Buffer Preparation in Life Science Research

Academic and commercial research labs integrate this buffer into the preparation of running and transfer buffers for nucleic acid and protein electrophoresis. The composition supports accurate band resolution by maintaining low conductivity and stable ionic profiles, critical to reproducibility in high-sensitivity gel and blotting assays.

Industry compliance standards

• Good Laboratory Practice (GLP) standards
• OECD Principles of GLP
• Institutional Research Ethics Guidelines
• Relevant ANSI/ISO standards for laboratory reagents

Typical usage ratio

• 20–50 mM in running buffers; concentrations adjusted by gel type (agarose, SDS-PAGE) and target nucleic acid or protein size

Downstream process integration

• Measured and dissolved during buffer tank setup prior to gel cassette assembly and electrophoresis protocol start; some protocols premix for extended storage

Final product types

• Agarose and polyacrylamide gel running solutions
• Northern/Southern/Western transfer buffers
• Blotting/wash working solutions
• Lab-scale DNA/RNA visualization gels